Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy
- PMID: 38470832
- DOI: 10.1093/eurjpc/zwae054
Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy
Conflict of interest statement
Conflict of interest: none declared.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
